Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.65 USD
-0.03 (-5.00%)
Updated May 2, 2024 04:00 PM ET
After-Market: $0.65 0.00 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATRA 0.65 -0.03(-5.00%)
Will ATRA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRA
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for ATRA
Commit To Buy Atara Biotherapeutics At $0.50, Earn 24.2% Annualized Using Options
Commit To Purchase Atara Biotherapeutics At $0.50, Earn 22.3% Annualized Using Options
12 Health Care Stocks Moving In Monday's After-Market Session
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)